21st January 2021
News
Sygnature Discovery Adopts OpenEye’s Orion™ Platform to Strengthen Molecular Design Services
19th January 2021
Awards News
Sygnature Discovery shortlisted for BioNow Company of the Year Award
18th January 2021
News
Sygnature upgrades western blotting capability with Jess instrument from Protein Simple
8th January 2021
News
Dr Paul Overton becomes Chief Commercial Officer (CCO) at Sygnature
16th December 2020
News
£3M investment to expand high-throughput screening and translational oncology capabilities
10th December 2020
News
What happened? A 2020 Recap!
9th October 2020
News
Sygnature Discovery wins Medilink Outstanding Achievement Award
24th September 2020
News
Sygnature Discovery expands DMPK capabilities with acquisition of XenoGesis
9th September 2020
News
Sygnature and RenaSci strengthen drug abuse leadership with appointment of Dr Andy Mead
23rd June 2020
News
Sygnature Discovery boosts senior management team with appointment of Dr Paul Overton
11th June 2020
Drug Discovery News
Sygnature assists New York Medical College in the fight against Covid-19
3rd June 2020
News Therapeutic Areas
Sygnature expands capabilities with acquisition of Alderley Oncology